Publications
623
Citations
18,646
Est. group size
~88
Recurring co-author estimate
Active years
20
Publishing since 2007
Jennifer A. Woyach's research focuses on chronic lymphocytic leukemia (CLL) and related blood cancers, particularly the development and testing of targeted drugs like BTK inhibitors (e.g., ibrutinib, pirtobrutinib) and venetoclax. Her work includes large multicenter clinical trials, studies of drug resistance mechanisms, and genomic characterization of CLL subtypes and disease progression (such as Richter transformation). This research is aimed at improving treatment sequencing and outcomes for patients with CLL and related lymphomas.
Publication output grew substantially from 2017 through a peak in 2023, followed by a decline in 2024-2026, though recent annual averages remain high compared to a decade ago.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Recurrent Genomic Alterations in <scp>BCRi</scp> ‐Experienced <scp>CLL</scp> Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up
American Journal of Hematology · 2026
- Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia
Journal of Clinical Oncology · 2026
- Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.
Journal of Clinical Oncology · 2026
- ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Journal of Clinical Oncology · 2026
- Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
The Lancet · 2026
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
Leukemia · 2025
- International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
Blood · 2025
- Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology · 2025
- Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Blood · 2025
- Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Blood Cancer Journal · 2025
- Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL
Blood · 2025
- Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy
Transplantation and Cellular Therapy · 2025
- The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics
Leukemia & lymphoma/Leukemia and lymphoma · 2025
- Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
Leukemia · 2025
- Precursor Hematologic Conditions: Diagnosis, Risk Stratification, Clinical Implications, and Management
American Society of Clinical Oncology Educational Book · 2025
- Blood×167
- Journal of Clinical Oncology×32
- Clinical Lymphoma Myeloma & Leukemia×28
- Leukemia×19
- Blood Advances×17
- Jeffrey A. Jones
Medicine · The Ohio State University
- Kerry A. Rogers
Medicine · The Ohio State University
- Seema A. Bhat
Medicine · The Ohio State University
- Jennifer A. Woyach
Medicine · The Ohio State University
- Gerard Lozanski
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile